ArticleHepatology international2026
Global trends in metabolic-associated hepatocellular carcinoma: genetic and socio-demographic drivers.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a primary driver of hepatocellular carcinoma (HCC). However, the synergistic impact of ancestral genetic susceptibility and socio-demographic transitions on the global MASLD-HCC landscape remains insufficiently quantified.
methodsUsing GBD 2021 data, we analyzed MASLD-HCC mortality and DALYs across 204 countries (1990-2021). Temporal trends were quantified using Joinpoint-derived average annual percent change (AAPC). We integrated ancestry-weighted risk allele frequencies (RAF) for five high-impact SNPs (PNPLA3, TM6SF2, MBOAT7, GCKR, HSD17B13) into GBD regions and utilized frontier and inequality analyses to evaluate socio-demographic drivers and 2050 projections.
resultsIn 2021, sub-Saharan Africa exhibited the highest mortality age-standardized rates (up to 1.09/100,000), while high-income super regions and Southern Latin America showed the most rapid historical increases (AAPC: 2.88% to 4.19%). Genetic-epidemiological mapping revealed that regional mortality burden was strongly correlated with PNPLA3 (ρ = 0.663, p = 0.001) and GCKR (ρ = 0.662, p = 0.001) risk frequencies, while HSD17B13 exerted a protective effect (ρ = -0.562, p = 0.008). The concentration index shifted toward zero (from - 0.0752 to - 0.0459), indicating an epidemiological convergence and global homogenization of the MASLD-HCC epidemic. By 2050, high-income super regions are projected to experience a disproportionate 52.11% surge in mortality, reflecting a significant delayed burden of cumulative metabolic risk exposure.
conclusionThe MASLD-HCC landscape is transitioning toward global prevalence, driven by genetic architecture and metabolic shifts. This narrowing inequality gap and impending mortality surge necessitate genetically-informed precision prevention and re-evaluation of metabolic-oncology surveillance.
Indexed as
Identifiers
42274972What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.